MET and sarcoma: The phase II clinical trials conducted by European Organization for Research and Treatment of Cancer (ClinicalTrials.gov identifier: NCT01524926) indicated that crizotinib against MET+ clear cell sarcoma showed comparable results with the results achieved by first-line single-agent doxorubicin in non-selected metastatic soft tissue sarcomas, as well as the results achieved by pazopanib in previously treated sarcoma patients in terms of progression-free survival 29.